Respiratory Disease News and Research RSS Feed - Respiratory Disease News and Research

Five centres awarded status of NHS Innovation Test Beds

Five centres awarded status of NHS Innovation Test Beds

NHS England has announced the five centres that have been awarded the status of Innovation Test Beds in which new approaches to healthcare provision will be assessed and adopted and two centres for the adoption of the Internet of Things (IoT) in healthcare. [More]
Diet rich in fiber may reduce risk of developing lung disease

Diet rich in fiber may reduce risk of developing lung disease

A diet rich in fiber may not only protect against diabetes and heart disease, it may reduce the risk of developing lung disease, according to new research published online, ahead of print in the Annals of the American Thoracic Society. [More]
Adults with long-term exposure to ozone face increased risk of respiratory and cardiovascular deaths

Adults with long-term exposure to ozone face increased risk of respiratory and cardiovascular deaths

Adults with long-term exposure to ozone (O3) face an increased risk of dying from respiratory and cardiovascular diseases, according to the study "Long-Term Ozone Exposure and Mortality in a Large Prospective Study" published online ahead of print in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. [More]
Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). [More]
UA researchers find genetic mutations associated with respiratory disease

UA researchers find genetic mutations associated with respiratory disease

Asthma affects more than 278 million people worldwide and can lead to serious consequences later in life. While current approved therapies address symptoms, they do not halt disease progression. [More]
Critically ill patients exposed to higher ozone levels more likely to develop ARDS

Critically ill patients exposed to higher ozone levels more likely to develop ARDS

Critically ill patients who are exposed to higher daily levels of ozone are more likely to develop acute respiratory disease syndrome (ARDS), according to a new study published online ahead of print in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. [More]
Study reveals effects of plain packaging on tobacco products among Australian Indigenous people

Study reveals effects of plain packaging on tobacco products among Australian Indigenous people

Following the introduction of plain packaging on tobacco products in 2012, Australian Aboriginal and Torres Strait Islander people were 12 per cent less likely to think certain tobacco brands were less harmful than others, a new study found. [More]
NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine. [More]
Music therapy in conjunction with standard rehabilitation benefits COPD patients

Music therapy in conjunction with standard rehabilitation benefits COPD patients

Patients with Chronic Obstructive Pulmonary Disease (COPD) and other chronic respiratory disorders who received music therapy in conjunction with standard rehabilitation saw an improvement in symptoms, psychological well-being and quality of life compared to patients receiving rehabilitation alone, according to a new study by researchers at The Louis Armstrong Center of Music and Medicine at Mount Sinai Beth Israel (MSBI). [More]
ATS commends President Obama for release of National Action Plan to combat TB

ATS commends President Obama for release of National Action Plan to combat TB

The American Thoracic Society applauds President Barack Obama and the Administration for the release of the National Action Plan to Combat Drug Resistant Tuberculosis (TB) today. [More]
Older men with sleep-disordered breathing at greater risk of developing atrial fibrillation

Older men with sleep-disordered breathing at greater risk of developing atrial fibrillation

Sleep-disordered breathing often predicts the development of atrial fibrillation (AF) in older men, according to U.S. researchers. [More]
Flavoring chemicals in e-cigarettes linked to severe respiratory disease

Flavoring chemicals in e-cigarettes linked to severe respiratory disease

Diacetyl, a flavoring chemical linked to cases of severe respiratory disease, was found in more than 75% of flavored electronic cigarettes and refill liquids tested by researchers at Harvard T.H. Chan School of Public Health. [More]
Reduced bone mass puts critically ill patients at greater risk for fractures

Reduced bone mass puts critically ill patients at greater risk for fractures

One year after being hospitalized in intensive care, patients have reduced bone mass that puts them at greater risk for fractures, according to a new study published online ahead of print in the American Journal of Respiratory and Critical Care Medicine. [More]
Doctors in Mexico show benefits of healthy diet, exercise in heart failure patients

Doctors in Mexico show benefits of healthy diet, exercise in heart failure patients

Doctors in Mexico have shown the benefits of a healthy diet and exercise in patients with heart failure, in research presented at the Mexican Congress of Cardiology 2015. [More]
Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD. [More]
WHO and the Government of Saudi Arabia work together to care for health issues of hajj pilgrims

WHO and the Government of Saudi Arabia work together to care for health issues of hajj pilgrims

As an estimated 2 million Muslims from 184 countries gather in Saudi Arabia’s holy city of Mecca to take part in the annual hajj pilgrimage, months of preparations to care for health issues of pilgrims are also coming together. [More]
Boehringer Ingelheim, BioMed X apply crowdsourcing approach to establish research team for identifying COPD treatment

Boehringer Ingelheim, BioMed X apply crowdsourcing approach to establish research team for identifying COPD treatment

Boehringer Ingelheim and BioMed X announced today that they have successfully applied a crowdsourcing approach to establish a research team of outstanding scientists from around the world with bright ideas, who will endeavor to identify new approaches for the treatment of patients with chronic obstructive pulmonary disease (COPD). [More]
Air pollution linked to overall increase in risk of death

Air pollution linked to overall increase in risk of death

In what is believed to be the largest, most detailed study of its kind in the United States, scientists at NYU Langone Medical Center and elsewhere have confirmed that tiny chemical particles in the air we breathe are linked to an overall increase in risk of death. [More]
Lannett enters into definitive agreement to purchase KU for $1.23 billion

Lannett enters into definitive agreement to purchase KU for $1.23 billion

Lannett Company, Inc. today announced that it has signed a definitive agreement to purchase Kremers Urban Pharmaceuticals Inc., the U.S. specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB S.A., for $1.23 billion, plus potential contingency payments. [More]
Temple-led study shows benefits of using digital health application for COPD patients

Temple-led study shows benefits of using digital health application for COPD patients

Early intervention facilitated by a digital health application for reporting symptoms of Chronic Obstructive Pulmonary Disease (COPD) provides key benefits for patients, according to the results of a Temple-led, two-year clinical study. [More]
Advertisement
Advertisement